PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Age 18-75 years, any gender. [+12]
Pregnant or lactating women. [+10]